Drug Profile
TAT Toxoid - Neovacs
Alternative Names: Tat Toxoid AIDS vaccine - NeovacsLatest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator Neovacs
- Developer sanofi pasteur
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 23 Mar 2009 No development reported - Phase-II for HIV infections in France (unspecified route)
- 23 Mar 2006 Phase-II clinical trials in HIV infections treatment in France (unspecified route)
- 21 Jan 2005 Aventis Pasteur is now called sanofi pasteur